- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
| home:starting [09.17.2017] – [Starting the Marshall Protocol] sallieq | home:starting [07.04.2022] (current) – external edit 127.0.0.1 | ||
|---|---|---|---|
| Line 23: | Line 23: | ||
| * [[home: | * [[home: | ||
| - | Important: | + | Important: |
| The MP Knowledge Base is partly based on that ongoing longitudinal study supported by the ARF and described below. | The MP Knowledge Base is partly based on that ongoing longitudinal study supported by the ARF and described below. | ||
| Line 33: | Line 33: | ||
| where this applies, we also would appreciate a brief summary annually or less frequently, to follow up your welfare, in order to make it possible for the research team to analyze outcomes over a ten year period or longer when possible. | where this applies, we also would appreciate a brief summary annually or less frequently, to follow up your welfare, in order to make it possible for the research team to analyze outcomes over a ten year period or longer when possible. | ||
| - | If you rarely post progress or take part in other discussion, you may find it necessary to ask for your personal topic to be reactivated. | + | If you rarely post progress or take part in other discussion, you may find it necessary to ask for your personal topic to be reactivated. |
| + | You may send an email to our [[mailto: | ||
| //Thank you// | //Thank you// | ||
home/starting.txt · Last modified: 07.04.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.